CClinicalTrials.gg
RecruitingNCT04370366Updated Mar 6, 2024

Imaging of Endolymphatic Hydrops at 7T MRI

An observational study in Meniere Disease, sponsored by King's College Hospital NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by King's College Hospital NHS Trust · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16
Ages
18 Years and older
Sex
All
01

Study summary

Imaging endolymphatic hydrops with 7T Sodium Imaging and 1.5 T gadolinium enhanced imaging: a comparison of diagnostic outcomes with 3T MRI

Duration of study 24 months

Study design Prospective cohort study

Number of patients 16 patients

  1. To evaluate whether imaging both 1.5T and 3T have an equivalent performance in terms of diagnosing MD ears with delayed post gadolinium enhanced MRI (applying quantitative and semi-quantitative analysis)
  2. To compare the diagnostic performance of Sodium Imaging at 7T (applying semi-quantitative analysis) with that of delayed post gadolinium enhanced 3T MRI in distinguishing symptomatic from asymptomatic Meniere's Disease (MD) ears.
Read the detailed description

Meniere's Disease is an inner ear disease characterised by progressive, fluctuating hearing loss and dizziness. Pathologically, it is characterised by endolymphatic hydrops. The diagnosis of Meniere's Disease can be elusive since it relies on the subjective reporting of symptoms and there is no definitive diagnostic test. Non-specific symptoms can occur in the early stages of Meniere's Disease and the disease progression can also fluctuate unpredictably. The cochlear and vestibular compartments may be differentially involved so there maybe clinical variability characterised by solely audiological or vestibular symptoms (1).

The structural correlate of MD is endolymphatic hydrops (EH) , in which the central smaller endolymphatic compartment of the inner ear (including the cochlear duct, saccule and utricle) expands into the surrounding peri-lymphatic chambers. Pathological studies of temporal bones in subjects with MD have demonstrated EH in most cases of Meniere's Disease (2) and its presence is required for, the diagnosis of 'certain Meniere's Disease' according to 1995 American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) guidelines (3). An accepted in vivo biological marker for endolymphatic hydrops has yet to be established. Recent developments in MRI technology and techniques have however allowed the demonstration of EH and the clinical application of these imaging studies is now being explored.

High resolution T2-weighted sequences are widely used for the demonstration of labyrinthine anatomy and pathology however they are unable to distinguish the endolymphatic from perilymphatic compartments and hence are generally unable to depict endolymphatic hydrops. The potential role of gadolinium in discriminating the endolymphatic chamber alone first became apparent in animal studies, since gadolinium was seen to accumulate in the perilymph but was excluded from the endolymph by the impermeable tight junctions. Intra-tympanic administration of gadolinium was initially explored, whereby high concentrations could enter the labyrinth through round window diffusion, however the evolution of clinically applicable high resolution sequences at 3T has allowed for gadolinium to be administered by the less invasive intravenous route. Delayed (4 hours post administration) gadolinium enhanced high resolution imaging is now used at a number of centres worldwide for the evaluation of Meniere's Disease patients, although acquisition and analysis methods continue to evolve. This is most frequently performed with 3D Fluid Attenuated Inversion Recovery with variable flip angles turbo spin echo sequence (3D SPACE FLAIR) or 3D real inversion recovery sequence (3D real IR. In order to corroborate the diagnosis of MD, the degree of EH in each cochlea and vestibule is semi-quantitatively graded (4,5) using various scales or may be quantitatively analysed by contouring the size of the two compartments. An ipsilateral increase in the perilymphatic enhancement is an additional MRI feature which is used to help distinguish MD ears.

The identification of cochlear or vestibular hydrops by MRI in vivo may support the diagnosis of Meniere's disease in cases with incomplete phenotypes and where there are other diagnostic considerations such as vestibular migraine or autoimmune ear disease. It may also facilitate early identification, thus guiding future treatment options for patients who have traditionally been required to take a watchful waiting approach to see how their symptoms may evolve or "trial-and-error" approach to management. The identification of bilateral endolymphatic hydrops in a patient with unilateral fluctuating aural symptoms might predict future bilateral disease and potentially influence therapeutic approaches. Establishing imaging as a biomarker in Meniere's disease may allow a contribution to diagnostic criteria and to define homogenous cohorts for longitudinal studies of natural history and treatment response.

However there are deficiencies with this MRI approach which we would like to address with an exploratory study of Meniere's disease patients on 1.5T and 7 Tesla MRI:

  1. Due to the small size of the inner ear structures being imaged, and the low concentration of gadolinium in the perilymph, 3T MRI is widely considered as being optimal for the diagnosis of MD. This maximises SNR and improves spatial resolution such that small inner ear structures (e.g. the cochlear duct) maybe delineated, improving precision and inter-observer agreement and diagnostic confidence of EH diagnosis. However there are many institutions which only have access to a 1.5-T system and this potentially limits their investigation of pateints with MD, unless patients are referred to another center. A global market analysis of the distribution of MRI scanners demonstrated that in 2019 there was a 71.3% share of 1.5-T scanners (6). Whilst there are some studies demonstrating feasibility of MD diagnosis on 1.5 T systems (7-9) there has been no study directly comparing the two approaches. It is therefore important to perform a study demonstrating equivalence of diagnostic outcomes at 1.5T and 3T.
  2. Gadolinium has an excellent safety record when used at low doses (0.1-0.3 mmol/kg) in patients with normal renal function. However, a causative relationship between gadolinium-based contrast agents and nephrogenic systemic fibrosis is described in patients with renal insufficiency, and there is also increasing evidence that they deposit in the human brain after multiple administrations, although the clinical significance of this remains uncertain (10). Therefore the development of non-contrast enhanced MRI technique is of considerable interest.

Whilst previous MRI approaches have concentrated on the difference in permeability to gadolinium to differentiate the endolymphatic and perilymphatic spaces of the inner ear, the difference in sodium concentrations between the two compartments is another differential feature which has not been explored. The perilymph and endolymph have unique ionic compositions suited to their functions in regulating electrochemical impulses necessary for hearing. The endolymph has a concentration of 1mM/l where the perilymph has a concentration of 140 mmol/l. Sodium imaging with MRI can provide quantitative measures of the sodium concentration in tissue (11,12). It utilizes the signal from the sodium nucleus to acquire images of the sodium biodistribution. Due to the low natural abundance of biological sodium, in comparison to water, as well as a rapid quadrupolar relaxation and lower gyromagnetic ratio the signal available is much lower than that of conventional proton MRI. Together, these properties make sodium very difficult to image with adequate signal-to-noise ratio (SNR) and hence it is most applicable to ultra-high-field MRI (7T) given the significant gain in signal strength.

An initial phase of 7T sodium imaging sequence development has been completed but there remain significant challenges to its application in the inner ear and it remains uncertain whether there will be sufficient spatial resolution and SNR, even at 7T. Therefore, the initially application of Sodium Imaging in MD should be in cases where there is known to be a maximal asymmetry in the size of the endolymphatic compartments on previous imaging studies in order to determine feasibility before determining whether it should be applied to a larger cohort. If Sodium Imaging of the inner ears is considered feasible then correlation of the semiquantitative analysis with the clinical diagnosis and with the size of the endolymphatic structures on reference standard delayed post gadolinium inversion recovery 3T MRI sequences would add validation to this approach.

  1. To evaluate whether imaging both 1.5T and 3T have an equivalent performance in terms of diagnosing MD ears with delayed post gadolinium enhanced MRI (applying quantitative and semi-quantitative analysis)
  2. To compare the diagnostic performance of Sodium Imaging at 7T (applying semi-quantitative analysis) with that of delayed post gadolinium enhanced 3T MRI in distinguishing symptomatic from asymptomatic Meniere's Disease (MD) ears.
02

Conditions studied

  • Meniere Disease
03

In context

Meniere Disease

73 studies on the registry are indexed under Meniere Disease; 14 are open to participants now.

Browse Meniere Disease studies →

Lead sponsor

King's College Hospital NHS Trust is the lead sponsor of 164 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Secondary care. Otology and audio-vestibular clinics Guy's and St Thomas' hospital

Inclusion criteria

  • Male or female, 18 years of age or older
  • The capacity to understand the patient information sheet and the ability to provide written informed consent
  • Unilateral audio-vestibular symptoms which satisfy 2015 Barany criteria for unilateral Meniere's Disease of less than 5 years duration
  • Would be offered clinical MRI scanning for confirmation of a Meniere's disease diagnosis as part of standard of care

Exclusion criteria

Exclusion Criteria:

  • Standard contraindications to 7T MRI
  • Known allergy to Gadolinium contrast
  • Calculated GFR \< 30 mls/min
  • Previous temporal bone surgery or trauma
  • Other known temporal bone pathology
  • Requirement for early post gadolinium sequences (e.g. autoimmune inner disease as a differential diagnosis)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The qualitative asymmetry of perilymphatic enhancement and the quantitative signal intensity ratio of the cochlea with delayed post gadolinium 3T and 1.5T.

    Time frame: 2.5 years

  2. The semi-quantitative scoring of endolymphatic hydrops and the quantitative volume of endolymphatic and perilymphatic structures with delayed post gadolinium 3T and 1.5T.

    Time frame: 2.5 years

  3. Semi-quantitative analysis (including ratios to internal references and the contralateral ear) of the vestibule on Sodium Imaging at 7T

    Time frame: 2.5 years

07

Study locations

1 of 1 sites recruiting
  • King's College London
    London, SW1P 4AL, United Kingdom
    • Steve Connor · Contact · 07816882304
    Recruiting
08

References and documents

Publications

  • Pyykko I, Nakashima T, Yoshida T, Zou J, Naganawa S. Meniere's disease: a reappraisal supported by a variable latency of symptoms and the MRI visualisation of endolymphatic hydrops. BMJ Open. 2013 Feb 14;3(2):e001555. doi: 10.1136/bmjopen-2012-001555. Print 2013. PubMed 23418296 ↗
  • Naganawa S, Sugiura M, Kawamura M, Fukatsu H, Sone M, Nakashima T. Imaging of endolymphatic and perilymphatic fluid at 3T after intratympanic administration of gadolinium-diethylene-triamine pentaacetic acid. AJNR Am J Neuroradiol. 2008 Apr;29(4):724-6. doi: 10.3174/ajnr.A0894. Epub 2008 Jan 9. PubMed 18184846 ↗
  • Barath K, Schuknecht B, Naldi AM, Schrepfer T, Bockisch CJ, Hegemann SC. Detection and grading of endolymphatic hydrops in Meniere disease using MR imaging. AJNR Am J Neuroradiol. 2014 Jul;35(7):1387-92. doi: 10.3174/ajnr.A3856. Epub 2014 Feb 13. PubMed 24524921 ↗
  • Attye A, Eliezer M, Boudiaf N, Tropres I, Chechin D, Schmerber S, Dumas G, Krainik A. MRI of endolymphatic hydrops in patients with Meniere's disease: a case-controlled study with a simplified classification based on saccular morphology. Eur Radiol. 2017 Aug;27(8):3138-3146. doi: 10.1007/s00330-016-4701-z. Epub 2016 Dec 20. PubMed 27999985 ↗
  • Venkatasamy A, Veillon F, Fleury A, Eliezer M, Abu Eid M, Romain B, Vuong H, Rohmer D, Charpiot A, Sick H, Riehm S. Imaging of the saccule for the diagnosis of endolymphatic hydrops in Meniere disease, using a three-dimensional T2-weighted steady state free precession sequence: accurate, fast, and without contrast material intravenous injection. Eur Radiol Exp. 2017;1(1):14. doi: 10.1186/s41747-017-0020-7. Epub 2017 Oct 9. PubMed 29708183 ↗
  • Simon F, Guichard JP, Kania R, Franc J, Herman P, Hautefort C. Saccular measurements in routine MRI can predict hydrops in Meniere's disease. Eur Arch Otorhinolaryngol. 2017 Dec;274(12):4113-4120. doi: 10.1007/s00405-017-4756-8. Epub 2017 Sep 26. PubMed 28951962 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04370366
Lead sponsor
King's College Hospital NHS Trust
Collaborators
King's College London, Guy's and St Thomas' NHS Foundation Trust
Responsible party
Sponsor
First posted
Apr 30, 2020
Start date
Jul 1, 2023
Primary completion
Jul 1, 2025 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Mar 6, 2024

Study contacts

Stephen EJ Connor, MRCP FRCR
Contact
steve.connor@nhs.net
07816882304
Irumee Pai, FRCS
Contact
irumee.pai@gstt.nhs.uk
Stephen EJ Connor, MRCP FRCR
principal investigator · King's College Hospital NHS Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion